Jump to content
RemedySpot.com

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Nov 11. [Epub ahead of print]

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for

antiviral therapies.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF.

Inserm, U748, Strasbourg, France; Université de Strasbourg, Strasbourg, France.

Abstract

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular

carcinoma. Preventive modalities are absent and the current antiviral treatment

is limited by resistance, toxicity, and high costs. Viral entry is required for

initiation, spread, and maintenance of infection, and thus is a promising target

for antiviral therapy. HCV entry is a highly orchestrated process involving

viral and host cell factors. These include the viral envelope glycoproteins E1

and E2, CD81, scavenger receptor BI, and tight junction proteins claudin-1 and

occludin. Recent studies in preclinical models and HCV-infected patients have

demonstrated that the virus has developed multiple strategies to escape host

immune responses during viral entry. These include evasion from neutralizing

antibodies and viral spread by cell-cell transmission. These challenges have to

be taken into account for the design of efficient antiviral strategies. Thus, a

detailed understanding of the mechanisms of viral entry and escape is a

prerequisite to define viral and cellular targets and develop novel preventive

and therapeutic antivirals. This review summarizes the current knowledge about

the molecular mechanisms of HCV entry into hepatocytes, highlights novel targets

and reviews the current preclinical and clinical development of compounds

targeting entry. Proof-of-concept studies suggest that HCV entry inhibitors are

a novel and promising class of antivirals widening the preventive and

therapeutic arsenal against HCV infection.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21146244 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Nov 11. [Epub ahead of print]

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for

antiviral therapies.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF.

Inserm, U748, Strasbourg, France; Université de Strasbourg, Strasbourg, France.

Abstract

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular

carcinoma. Preventive modalities are absent and the current antiviral treatment

is limited by resistance, toxicity, and high costs. Viral entry is required for

initiation, spread, and maintenance of infection, and thus is a promising target

for antiviral therapy. HCV entry is a highly orchestrated process involving

viral and host cell factors. These include the viral envelope glycoproteins E1

and E2, CD81, scavenger receptor BI, and tight junction proteins claudin-1 and

occludin. Recent studies in preclinical models and HCV-infected patients have

demonstrated that the virus has developed multiple strategies to escape host

immune responses during viral entry. These include evasion from neutralizing

antibodies and viral spread by cell-cell transmission. These challenges have to

be taken into account for the design of efficient antiviral strategies. Thus, a

detailed understanding of the mechanisms of viral entry and escape is a

prerequisite to define viral and cellular targets and develop novel preventive

and therapeutic antivirals. This review summarizes the current knowledge about

the molecular mechanisms of HCV entry into hepatocytes, highlights novel targets

and reviews the current preclinical and clinical development of compounds

targeting entry. Proof-of-concept studies suggest that HCV entry inhibitors are

a novel and promising class of antivirals widening the preventive and

therapeutic arsenal against HCV infection.

European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21146244 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...